Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smartphone app curb HIV risk in south Korea's young gay men?

NCT ID NCT07741123

Prevention Sponsor: Seul Ki Choi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This pilot trial tests a mobile app called Bandi, designed to support HIV prevention among young men who have sex with men in South Korea. Participants are randomly assigned to either the full app, which includes interactive health content, peer forums, a sexual health log, and a clinic finder, or a basic version with only informational articles and a clinic finder. Over three months, researchers compare the two groups to see if the full app leads to higher rates of HIV testing and lower sexual risk behaviors. The study aims to learn if the app is acceptable, easy to use, and helpful for this community.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Bandi mobile application (full access) - a culturally adapted digital HIV prevention app with interactive content, peer forums, sexual health tracking, clinic locator, and gamification.
What this could lead to
If successful, this app could offer a scalable, engaging way to improve HIV prevention and sexual health among young men who have sex with men in South Korea.
What could go wrong
This is a small pilot study, so results may not be conclusive. The app's impact on HIV testing and risk behavior may be limited by user engagement or cultural fit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 35 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male sex assigned at birth and current male gender identity * Aged 18 to 35 years * Current residence in the Seoul Metropolitan area * Korean nationality * Self-identify as a sexual minority (e.g., gay, bisexual, queer, or other non-heterosexual identity) * HIV-negative or HIV-unaware serostatus * Report at least 1 episode of condomless anal intercourse with a male partner in the prior 6 months Exclusion Criteria: * Assigned female at birth or do not currently identify as male * Younger than 18 or older than 35 years of age * Non-residence in the Seoul Metropolitan area * Do not hold Korean nationality * Do not identify as a sexual minority * Known HIV-positive status * No reported episodes of condomless anal intercourse with a male partner in the prior 6 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Digital health are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Risk Reduction Behavior Social Stigma HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Digital health HIV infections HIV prevention and care Risk reduction behavior

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ewha Womans University

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.